메뉴 건너뛰기




Volumn 377, Issue 8, 2017, Pages 783-784

Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma

Author keywords

[No Author keywords available]

Indexed keywords

CD19 DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL PRODUCT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IMMUNOLOGIC AGENT; JCAR017; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; CD19 ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR;

EID: 85028448895     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1704610     Document Type: Letter
Times cited : (170)

References (5)
  • 1
    • 84923118622 scopus 로고    scopus 로고
    • Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor
    • Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015;33:540-9.
    • (2015) J Clin Oncol , vol.33 , pp. 540-549
    • Kochenderfer, J.N.1    Dudley, M.E.2    Kassim, S.H.3
  • 2
    • 84988805188 scopus 로고    scopus 로고
    • Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19− Specific chimeric antigen receptor-modified T cells
    • Turtle CJ, Hanafi LA, Berger C, et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19− specific chimeric antigen receptor-modified T cells. Sci Transl Med 2016;8:355ra116.
    • (2016) Sci Transl Med , vol.8 , pp. 355ra116
    • Turtle, C.J.1    Hanafi, L.A.2    Berger, C.3
  • 3
    • 84874534353 scopus 로고    scopus 로고
    • Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas
    • Korfel A, Elter T, Thiel E, et al. Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas. Haematologica 2013; 98:364-70.
    • (2013) Haematologica , vol.98 , pp. 364-370
    • Korfel, A.1    Elter, T.2    Thiel, E.3
  • 4
    • 85038567289 scopus 로고    scopus 로고
    • Treatment of secondary central nervous system lymphoma with intra-thecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: Results of the HOVON 80 phase 2 study
    • August 17 Epub ahead of print
    • Doorduijn JK, van Imhoff GW, van der Holt B, et al. Treatment of secondary central nervous system lymphoma with intra-thecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study. Hematol Oncol 2016 August 17 (Epub ahead of print).
    • (2016) Hematol Oncol
    • Doorduijn, J.K.1    Van Imhoff, G.W.2    Van Der Holt, B.3
  • 5
    • 84876325876 scopus 로고    scopus 로고
    • Chimeric antigen receptor–modified T cells for acute lymphoid leukemia
    • Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor–modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509-18.
    • (2013) N Engl J Med , vol.368 , pp. 1509-1518
    • Grupp, S.A.1    Kalos, M.2    Barrett, D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.